Ophthalmology Times

NovaBridge, Visara report positive phase 2a results for dual VEGF-A/ANG-2 inhibitor VIS-101

VIS-101 targets VEGF-A and ANG-2 with a bispecific tetravalent format designed to increase ligand affinity and binding capacity, aiming to improve anatomic/visual outcomes and extend dosing intervals.
Ophthalmology Times

FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...
Ophthalmology Times

Real-world approaches to managing DME: Improving durability, drying, and patient burden

Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...
Ophthalmology Times

Cost, coverage, and access challenges in geographic atrophy treatment

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss the financial barriers facing patients with geographic atrophy, including ...
Ophthalmology Times

Mixed signals and mounting frustrations: ophthalmologists on dry eye disease

Fluctuating vision is the most frequently cited complaint, exceeding classic discomfort symptoms, and may divert patients toward refractive explanations before DED is recognized and treated.
Ophthalmology Times

Patient selection and counseling for complement inhibitor therapy in geographic atrophy

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss how retina specialists identify appropriate candidates for complement inhibitor therapy in geographic atrophy, set patient expectations, and monitor ...
Ophthalmology Times

Pegcetacoplan Saves 1.5 Years of GA Lesion Progression in GALE Extension, With Dilsher Dhoot, MD

Earlier pegcetacoplan treatment preserved twice as much retinal tissue compared to delayed treatment in patients with geographic atrophy (GA) secondary to age-related macular dege ...
Ophthalmology Times

Harrow receives FDA IND clearance for phase 3 trial of TRIESENCE after cataract surgery

FDA IND clearance enables a phase 3 program evaluating TRIESENCE for postoperative ocular inflammation and pain following cataract surgery, aiming to broaden on-label use beyond current intraocular ...
ophthalmologytimes

Tattoo-associated uveitis: An emerging eye health challenge

Tattoo pigment–triggered ocular inflammation commonly presents with concurrent tattoo granulomatous changes and typically manifests as bilateral anterior uveitis, with reported posterior sequelae ...
ophthalmologytimes

SpyGlass Pharma reports positive 12-month phase I/II results for BIM-IOL System in glaucoma and ocular hypertension

Two non-bioerodible pads at the optic–haptic junction of a monofocal IOL release bimatoprost into aqueous humor for >3 years while remaining outside the visual axis. Randomization (2:1:1) compared 78 ...
ophthalmologytimes

Ophthalmic drug shortages more frequent, longer lasting than average

Ophthalmic medications comprised 12.3% of validated shortages, yet represented ~15% of active shortages, with annual share fluctuating from 6% to 28% across 2001–2024. Shortages were nearly evenly ...
ophthalmologytimes

Advancing geographic atrophy care: Long-term data and real-world insights

Joseph A. Anaya, MD, MBA, and Ashkan M. Abbey, MD, FASRS, FAAO, consider how emerging treatments impact patient vision, functional outcomes, and practical management ...